Illumina Inc (ILMN):医療機器:M&Aディール及び事業提携情報

◆英語タイトル:Illumina Inc (ILMN) - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA904C7217
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:157
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥34,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥68,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥102,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Illumina Inc (Illumina) provides genomic sequencing and array-based solutions for genetic analysis in the areas of molecular diagnostics, translational and consumer genomics, and oncology. The company’s portfolio encompasses sequencing tools and systems; sequencing kits and reagents; microarray kits and reagents; molecular biology reagents; and arrays and reagents. It offers human whole-genome sequencing; microarray services; and instrument services, training and consulting. Illumina caters its services to pharmaceutical companies, genomic research centers, academic institutions, biotechnology companies and clinical research organizations. The company sells its products through direct sales and distributors in the Americas, Asia-Pacific, Europe, the Middle East and Africa. Illumina is headquartered in San Diego, California, the US.

Illumina Inc (ILMN) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 7
List of Figures 8
Illumina Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 10
Illumina Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 11
Illumina Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 12
Illumina Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 13
Illumina Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 14
Illumina Inc, Medical Equipment, Deal Details 19
Venture Financing 19
Grail Raises USD300 Million in Series C Financing 19
Cernostics Raises USD2.5 Million in Series A1 Financing 20
SerImmune Raises USD8 Million in Venture Financing 21
Grail Raises USD914 Million in First Tranche of Series B Financing 22
Human Longevity Raises USD220 Million in Series B Financing Round 24
Grail Bio Raises USD100 Million in Series A Financing 26
Vitagene Raises Funds in Financing Round 27
23andMe Raises USD115 Million in Series E Financing 28
Baebies Raises USD13 Million in Financing Round 30
Verinata Health (Artemis Health) Secures USD1.2 Million in Seed Funding 31
Oxford Nanopore Raises US$64 Million In Venture Financing 32
GenoLogics Life Sciences Raises USD0.9 Million in Venture Financing 34
GenoLogics Life Sciences Raises Additional USD0.5 Million in Venture Financing 35
GenoLogics Life Sciences Raises USD1.3 Million in Venture Financing 36
Private Equity 37
Mubadala GE Capital and SoftBank Vision Fund May Acquire GRAIL 37
Partnerships 38
Vitrolife Enters into Licensing Agreement with Illumina 38
CareDx Enters into Licensing and Commercialization Agreement with Illumina 39
Skyline Medical Enters into Licensing Agreement with Illumina 40
Illumina Enters Into Licensing Agreement With Quest Diagnostics 41
Peter MacCallum Cancer Centre Enters Into Licensing Agreement With GenoLogics Life Sciences Software For Clarity LIMS 42
Genecast Biotechnology Enters into Partnership Agreement with Illumina 43
Yissum Enters into Agreement with GRAIL 44
Bristol-Myers Squibb and Illumina Enter into Partnership Agreement 45
Illumina and Loxo Oncology Enter into Partnership 46
Illumina and KingMed Diagnostics Enter into Agreement 47
Illumina Enters into Agreement with Pillar Biosciences 48
Edico Genome Enters Into Partnership With Fabric Genomics 49
Hamilton Robotics Partners with Illumina 50
Lucigen Enters into Distribution Agreement with Illumina 51
Kailos Genetics Enters into Co-Marketing Agreement with Illumina 52
Analytik Jena Enters into Co-Development Agreement with Illumina 53
Bristol-Myers Squibb Plans to Enter into Research Agreement with GRAIL 54
Invivoscribe Tech Enters into Agreement with Illumina 55
IBM Watson Health Enters into Agreement with Illumina 56
Koninklijke Philips Enters into Agreement with Illumina 57
Illumina Enters into Agreement with Mayo Clinic 58
Q2 Solutions Enters into Co-Development Agreement with Illumina 59
Sophia Genetics Enters into Co-Marketing Agreement with Illumina 60
Illumina Enters into Agreement with FlowJo 61
Personal Genome Diagnostics Enters into Co-Development Agreement with Illumina 62
MolecularMD Enters into Agreement with Illumina 63
ArcherDX Enters into Co-Development Agreement with Illumina 64
Genomics England Partners with Illumina 65
Bio-Rad Laboratories Enters into Partnership with Illumina 66
Novogene Enters into Co-Development Agreement with Illumina 67
Almac Diagnostics Enters into Agreement with Illumina 68
Centers for Disease Control and Prevention Enters into Research Agreement with Edico Genome 69
Asuragen to Enter into Agreement with Illumina 70
Edico Genome Enters into Agreement with HudsonAlpha Institute for Biotechnology 71
Illumina Enters into Co-Development Agreement with Annoroad Gene Technology 72
Merck Serono Enters into Co- Development Agreement with Illumina 73
Victorian Clinical Genetics Enters into Agreement with Illumina to Develop NIPT 74
BioMerieux Enters into Co-Development Agreement with Illumina 75
Sequenta Enters into Agreement with Illumina to Commercialize In Vitro Diagnostic Kit 76
Reprogenetics Enters into R&D Agreement with Illumina for Next-Generation In-Vitro Fertilization Sequencing Systems 77
HTG Molecular Diagnostics Amends its Agreement with Illumina to Develop IVD Kits for Sequencing Tests 78
Illumina Partners with AstraZeneca, Janssen and Sanofi to Develop NGS-Based Oncology Test System 79
Illumina Enters Into Co-Development Agreement With Amgen For Oncology Companion Diagnostic Test 80
Pathogenica Enters Into Co-Marketing Agreement With Illumina 81
Teva Pharma Enters Into Co-Marketing Agreement With Verinata Health For Verifi Test 82
Illumina Enters Into Co-Marketing Agreement With Hamilton Robotics 83
SynapDx Enters Into Co-Development Agreement With Illumina For Autism Diagnostic Tools 84
Sonic Healthcare Enters Into Co-Marketing Agreement With Verinata Health For Verifi Test 85
Newbridge Pharma Enters Into Co-Marketing Agreement With Verinata Health For Verifi Test 86
NextBio Enters Into Research Agreement With Emory University And Aflac Cancer Center For Medulloblastoma Biomarkers 87
PerkinElmer Enters Into Co-Marketing Agreement With Verinata Health For Verifi Test 88
NextBio Enters Into Agreement With Winship Cancer Institute of Emory University For Myeloma Biomarkers 89
Illumina Enters Into Technology Integration Agreement With Partners HealthCare System 90
GenMark Diagnostics Enters Into Co-Development Agreement With Advanced Liquid Logic For Integrated Diagnostic Platform 91
Merger 92
Grail Merges with Cirina 92
Equity Offering 93
Grail May Raise USD1 Billion in IPO 93
Debt Offering 94
Illumina Prices Private Placement of Notes Due 2023 for USD650 Million 94
Illumina Raises USD550 Million in Private Placement of Notes Due 2019 96
Illumina Raises USD450 Million in Private Placement of 0.5% Notes Due 2021 97
Asset Transactions 98
Human Longevity Acquires HiSeq X Ten Sequencing Systems From Illumina 98
Pathway Genomics Acquires MiSeqDx From Illumina 99
Novogene Acquires HiSeq X Ten Sequencing System From Illumina 100
Acquisition 101
Illumina Acquires Edico Genome 101
Thermo Fisher Scientific May Acquire Illumina for USD30 Billion 102
Illumina Acquires Conexio Genomics 103
Illumina Acquires Myraqa, In-Vitro Diagnostics Company 104
Illumina Acquires NextBio, Clinical and Genomic Informatics Company 105
Illumina Completes Sale Of 13.5% Stake In Oxford Nanopore For US$91 Million 106
Illumina Acquires Advanced Liquid Logic 107
Illumina Completes Acquisition Of Verinata Health 108
Illumina Acquires Moleculo, Long-Read Sequencing Technology Developer 110
Illumina Acquires BlueGnome, Provider Of Cytogenetics And In Vitro Fertilization Screening Solutions 111
Illumina Inc – Key Competitors 112
Illumina Inc – Key Employees 113
Illumina Inc – Locations And Subsidiaries 114
Head Office 114
Other Locations & Subsidiaries 114
Joint Venture 116
Recent Developments 117
Financial Announcements 117
Jul 30, 2018: Illumina Reports Financial Results for Second Quarter of Fiscal Year 2018 117
Apr 24, 2018: Illumina Reports Financial Results for First Quarter of Fiscal Year 2018 119
Jan 30, 2018: Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2017 120
Oct 24, 2017: Illumina Reports Financial Results for Third Quarter of Fiscal Year 2017 122
Aug 01, 2017: llumina Reports Strong Financial Results for Second Quarter of Fiscal Year 2017 123
Aug 01, 2017: Illumina Reports Strong Financial Results for Second Quarter of Fiscal Year 2017 124
Apr 25, 2017: Illumina Reports Financial Results for First Quarter of Fiscal Year 2017 125
Jan 31, 2017: Illumina Reports Full Financial Results for Fourth Quarter and Fiscal Year 2016 126
Research And Development 128
Feb 28, 2017: Illumina Announces the iHope Network, an Expansion of Its iHope Philanthropic Clinical Whole Genome Sequencing Program 128
Corporate Communications 129
Mar 12, 2018: Illumina Names Dr. Phil Febbo Chief Medical Officer 129
Dec 11, 2017: Illumina Names Aimee Hoyt Chief People Officer, Bringing 20+ Years of Senior Human Resources Leadership from Global Technology Companies 130
Nov 08, 2017: Illumina Names Gary S. Guthart, Ph.D., to its Board of Directors, Adding Decades of Leadership Experience in Healthcare 131
May 22, 2017: Illumina Names Mark Van Oene Chief Commercial Officer, Sales Leader Brings Genomics Expertise and Strong Commercial Leadership Experience to the Role 132
Feb 20, 2017: Illumina Names John W. Thompson to Its Board of Directors, Bringing More Than 40 Years of Technology Leadership to Illumina 133
Jan 27, 2017: Illumina Names Caroline Dorsa to Its Board of Directors, Adding Over 30 Years of Leadership Experience in the Healthcare, Telecommunications and Energy Industries 134
Jan 03, 2017: Illumina Taps Garret Hampton, One of the World’s Leading Clinical Genomics Experts, to Head its Clinical Genomics Unit 135
Legal and Regulatory 136
Jul 03, 2017: Premaitha Health Litigation Update 136
Government and Public Interest 137
Feb 12, 2018: New GUINNESS WORLD RECORDS Title Set for Fastest Genetic Diagnosis 137
Product News 139
Sep 13, 2018: ABclonal Technology unveils Next-Generation Sequencing kits for Illumina sequencing platforms 139
Oct 17, 2017: Dr. David Walt of Wyss Institute to Speak at Powering Precision Health 2017 140
Jul 13, 2017: World-leading Cancer Researchers First in UK to Receive Novaseq – The Latest Genome Sequencing Technology 141
Jan 09, 2017: Illumina and Bio-Rad Launch Solution for Single-Cell Genomic Sequencing to Enable Robust Study of Complex Diseases 143
Jan 09, 2017: Illumina Introduces the NovaSeq Series—a New Architecture Designed to Usher in the $100 Genome 144
Other Significant Developments 145
Oct 11, 2018: Almac Group Invests in Cutting Edge Next Generation Sequencing Capabilities for Bio Pharma Clients 145
Jul 12, 2018: OrigiMed Collaborates with Illumina to Further Develop and Promote its Advanced Clinical Molecular Tumor Applications 146
May 07, 2018: Genome Medical Enters Employer Market with Diverse Genetic Health Programs and Wave of New Partners 147
Jan 08, 2018: Thermo Fisher Scientific and Illumina Sign Agreement to Provide Research Market Broader Access to Ion AmpliSeq Technology 148
Oct 16, 2017: Illumina Releases NovaSeq S4 Flow Cell and NovaSeq Xp Workflow 149
Jun 26, 2017: Genomics England Adopts Illumina’s BaseSpace Variant Interpreter for Cancer 150
Jun 01, 2017: Philips and Illumina team up with Navican, an Intermountain Healthcare Company, to Accelerate the Delivery of Precision Medicine to Health Systems Worldwide 151
Apr 20, 2017: Personalis Orders Ten Illumina NovaSeq 6000 Systems for Immuno-Oncology Genomics and Large-Scale Whole Genome Sequencing 153
Apr 10, 2017: CloudHealth Genomics Makes China’s First Sequencing Data Available Using Illumina’s NovaSeq 6000 154
Apr 03, 2017: Illumina Advances the Use of Genomics in Precision Oncology, Donates Thousands of Somatic Interpretations to CIViC 155
Apr 03, 2017: Novogene Adds 25 Illumina NovaSeq Sequencers 156
Appendix 157
Methodology 157
About GlobalData 157
Contact Us 157
Disclaimer 157

List of Tables
Illumina Inc, Medical Equipment, Key Facts, 2017 2
Illumina Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 2
Illumina Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 10
Illumina Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 11
Illumina Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 12
Illumina Inc, Deals By Market, 2012 to YTD 2018 13
Illumina Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 14
Grail Raises USD300 Million in Series C Financing 19
Cernostics Raises USD2.5 Million in Series A1 Financing 20
SerImmune Raises USD8 Million in Venture Financing 21
Grail Raises USD914 Million in First Tranche of Series B Financing 22
Human Longevity Raises USD220 Million in Series B Financing Round 24
Grail Bio Raises USD100 Million in Series A Financing 26
Vitagene Raises Funds in Financing Round 27
23andMe Raises USD115 Million in Series E Financing 28
Baebies Raises USD13 Million in Financing Round 30
Verinata Health (Artemis Health) Secures USD1.2 Million in Seed Funding 31
Oxford Nanopore Raises US$64 Million In Venture Financing 32
GenoLogics Life Sciences Raises USD0.9 Million in Venture Financing 34
GenoLogics Life Sciences Raises Additional USD0.5 Million in Venture Financing 35
GenoLogics Life Sciences Raises USD1.3 Million in Venture Financing 36
Mubadala GE Capital and SoftBank Vision Fund May Acquire GRAIL 37
Vitrolife Enters into Licensing Agreement with Illumina 38
CareDx Enters into Licensing and Commercialization Agreement with Illumina 39
Skyline Medical Enters into Licensing Agreement with Illumina 40
Illumina Enters Into Licensing Agreement With Quest Diagnostics 41
Peter MacCallum Cancer Centre Enters Into Licensing Agreement With GenoLogics Life Sciences Software For Clarity LIMS 42
Genecast Biotechnology Enters into Partnership Agreement with Illumina 43
Yissum Enters into Agreement with GRAIL 44
Bristol-Myers Squibb and Illumina Enter into Partnership Agreement 45
Illumina and Loxo Oncology Enter into Partnership 46
Illumina and KingMed Diagnostics Enter into Agreement 47
Illumina Enters into Agreement with Pillar Biosciences 48
Edico Genome Enters Into Partnership With Fabric Genomics 49
Hamilton Robotics Partners with Illumina 50
Lucigen Enters into Distribution Agreement with Illumina 51
Kailos Genetics Enters into Co-Marketing Agreement with Illumina 52
Analytik Jena Enters into Co-Development Agreement with Illumina 53
Bristol-Myers Squibb Plans to Enter into Research Agreement with GRAIL 54
Invivoscribe Tech Enters into Agreement with Illumina 55
IBM Watson Health Enters into Agreement with Illumina 56
Koninklijke Philips Enters into Agreement with Illumina 57
Illumina Enters into Agreement with Mayo Clinic 58
Q2 Solutions Enters into Co-Development Agreement with Illumina 59
Sophia Genetics Enters into Co-Marketing Agreement with Illumina 60
Illumina Enters into Agreement with FlowJo 61
Personal Genome Diagnostics Enters into Co-Development Agreement with Illumina 62
MolecularMD Enters into Agreement with Illumina 63
ArcherDX Enters into Co-Development Agreement with Illumina 64
Genomics England Partners with Illumina 65
Bio-Rad Laboratories Enters into Partnership with Illumina 66
Novogene Enters into Co-Development Agreement with Illumina 67
Almac Diagnostics Enters into Agreement with Illumina 68
Centers for Disease Control and Prevention Enters into Research Agreement with Edico Genome 69
Asuragen to Enter into Agreement with Illumina 70
Edico Genome Enters into Agreement with HudsonAlpha Institute for Biotechnology 71
Illumina Enters into Co-Development Agreement with Annoroad Gene Technology 72
Merck Serono Enters into Co- Development Agreement with Illumina 73
Victorian Clinical Genetics Enters into Agreement with Illumina to Develop NIPT 74
BioMerieux Enters into Co-Development Agreement with Illumina 75
Sequenta Enters into Agreement with Illumina to Commercialize In Vitro Diagnostic Kit 76
Reprogenetics Enters into R&D Agreement with Illumina for Next-Generation In-Vitro Fertilization Sequencing Systems 77
HTG Molecular Diagnostics Amends its Agreement with Illumina to Develop IVD Kits for Sequencing Tests 78
Illumina Partners with AstraZeneca, Janssen and Sanofi to Develop NGS-Based Oncology Test System 79
Illumina Enters Into Co-Development Agreement With Amgen For Oncology Companion Diagnostic Test 80
Pathogenica Enters Into Co-Marketing Agreement With Illumina 81
Teva Pharma Enters Into Co-Marketing Agreement With Verinata Health For Verifi Test 82
Illumina Enters Into Co-Marketing Agreement With Hamilton Robotics 83
SynapDx Enters Into Co-Development Agreement With Illumina For Autism Diagnostic Tools 84
Sonic Healthcare Enters Into Co-Marketing Agreement With Verinata Health For Verifi Test 85
Newbridge Pharma Enters Into Co-Marketing Agreement With Verinata Health For Verifi Test 86
NextBio Enters Into Research Agreement With Emory University And Aflac Cancer Center For Medulloblastoma Biomarkers 87
PerkinElmer Enters Into Co-Marketing Agreement With Verinata Health For Verifi Test 88
NextBio Enters Into Agreement With Winship Cancer Institute of Emory University For Myeloma Biomarkers 89
Illumina Enters Into Technology Integration Agreement With Partners HealthCare System 90
GenMark Diagnostics Enters Into Co-Development Agreement With Advanced Liquid Logic For Integrated Diagnostic Platform 91
Grail Merges with Cirina 92
Grail May Raise USD1 Billion in IPO 93
Illumina Prices Private Placement of Notes Due 2023 for USD650 Million 94
Illumina Raises USD550 Million in Private Placement of Notes Due 2019 96
Illumina Raises USD450 Million in Private Placement of 0.5% Notes Due 2021 97
Human Longevity Acquires HiSeq X Ten Sequencing Systems From Illumina 98
Pathway Genomics Acquires MiSeqDx From Illumina 99
Novogene Acquires HiSeq X Ten Sequencing System From Illumina 100
Illumina Acquires Edico Genome 101
Thermo Fisher Scientific May Acquire Illumina for USD30 Billion 102
Illumina Acquires Conexio Genomics 103
Illumina Acquires Myraqa, In-Vitro Diagnostics Company 104
Illumina Acquires NextBio, Clinical and Genomic Informatics Company 105
Illumina Completes Sale Of 13.5% Stake In Oxford Nanopore For US$91 Million 106
Illumina Acquires Advanced Liquid Logic 107
Illumina Completes Acquisition Of Verinata Health 108
Illumina Acquires Moleculo, Long-Read Sequencing Technology Developer 110
Illumina Acquires BlueGnome, Provider Of Cytogenetics And In Vitro Fertilization Screening Solutions 111
Illumina Inc, Key Competitors 112
Illumina Inc, Key Employees 113
Illumina Inc, Other Locations 114
Illumina Inc, Subsidiaries 114
Illumina Inc, Joint Venture 116

List of Figures
Illumina Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 2
Illumina Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 2
Illumina Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 2
Illumina Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 2
Illumina Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 10
Illumina Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 11
Illumina Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 12
Illumina Inc, Medical Equipment, Deals by Market, 2012 to YTD 2018 13

★海外企業調査レポート[Illumina Inc (ILMN):医療機器:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Charles River Laboratories International, Inc.:戦略・SWOT・企業財務分析
    Charles River Laboratories International, Inc. - Strategy, SWOT and Corporate Finance Report Summary Charles River Laboratories International, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, ope …
  • Neurimmune Holding AG-製薬・医療分野:企業M&A・提携分析
    Summary Neurimmune Holding AG (Neurimmune), formerly known as Neurimmune Therapeutics AG is a biopharmaceutical company that develops immunotherapeutics. The company’s pipeline products include human-derived monoclonal antibodies developed for the treatment and prevention of human disorders with a f …
  • Cyxone AB-製薬・医療分野:企業M&A・提携分析
    Summary Cyxone AB (Cyxone) is a biopharmaceutical company that develops cyclotide drugs for immune-related diseases. The company’s lead product include T20K, a compound to inhibit pro-inflammatory cytokines, such as IL2 that helps to reduce clinical symptoms in an animal model for multiple sclerosis …
  • Endesa SA (ELE):電力:M&Aディール及び事業提携情報
    Summary Endesa SA (Endesa), a subsidiary of Enel SpA, is an electric utility. It generates, distributes, and sells electricity. The company produces electricity in hydro, thermal, nuclear, combined cycle, and renewable and cogeneration plants. Endesa also supplies electricity and gas, and provides o …
  • Bellerophon Therapeutics Inc (BLPH):企業の財務・戦略的SWOT分析
    Summary Bellerophon Therapeutics Inc (Bellerophon Therapeutics), formerly Known as Bellerophon Therapeutics LLC is a clinical-stage biotherapeutics company that focuses on the development of therapies for the treatment of cardiopulmonary diseases. The company’s lead investigational cardiopulmonary p …
  • Rockwell Medical Inc (RMTI):医療機器:M&Aディール及び事業提携情報
    Summary Rockwell Medical Inc (Rockwell) is a biopharmaceutical company that focuses on the development, manufacture and distribution of products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis. The company’s major products include Triferic, an iron d …
  • G4S Plc (GFS):企業の財務・戦略的SWOT分析
    G4S Plc (GFS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pot …
  • Copperbelt Energy Corporation Plc (CEC):企業の財務・戦略的SWOT分析
    Copperbelt Energy Corporation Plc (CEC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • Gedeon Richter Plc:戦略・SWOT・企業財務分析
    Gedeon Richter Plc - Strategy, SWOT and Corporate Finance Report Summary Gedeon Richter Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Jadason Enterprises Limited (J03):企業の財務・戦略的SWOT分析
    Jadason Enterprises Limited (J03) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Sorgenia SpA:電力:M&Aディール及び事業提携情報
    Summary Sorgenia SpA (Sorgenia) is an electricity generator and energy utilities company. The company operates in the energy and natural gas sector. It produces, imports, and sells electricity and gas. The company also offers various integrated power saving equipment and services. Sorgenia is a grou …
  • Dixons Carphone plc:企業のM&A・事業提携・投資動向
    Dixons Carphone plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Dixons Carphone plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), …
  • Frontage Laboratories Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Frontage Laboratories Inc (Frontage), a subsidiary of Hangzhou Tigermed Consulting Co Ltd is a contract research organization that offers early phase drug development and other research services. The organization’s services include clinical research, drug metabolism and pharmacokinetic, CMC …
  • Fenner PLC (FENR):企業の財務・戦略的SWOT分析
    Summary Fenner PLC (Fenner) a subsidiary of Michelin SCA, is a provider of reinforced polymer technology. The company operates in the areas of advanced engineered products and engineered conveyor solutions. Its product portfolio includes heavyweight conveyor belt, high performance polymer components …
  • Koch Enterprises, Inc.:企業の戦略的SWOT分析
    Koch Enterprises, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Akcea Therapeutics Inc (AKCA):製薬・医療:M&Aディール及び事業提携情報
    Summary Akcea Therapeutics Inc (Akcea Therapeutics), a subsidiary of Ionis Pharmaceuticals Inc, is a developer and commercializer of drugs to treat patients with cardiometabolic diseases caused by lipid disorders. The company’s drugs are designed based on advanced antisense technology. Its pipeline …
  • Tulip Diagnostics (P) Ltd:医療機器:M&Aディール及び事業提携情報
    Summary Tulip Diagnostics (P) Ltd (Tulip Diagnostics), a subsidiary of Tulip Group is a diagnostic company that manufactures and markets in vitro diagnostic reagents and kits. The company provides assay systems for immunohaematology, hematology, rheumatology, infectious diseases, hemostasis, and ins …
  • SonarMed Inc-医療機器分野:企業M&A・提携分析
    Summary SonarMed Inc (SonarMed) is a medical device company that develops endotrachael systems used for the inhalation and ventilation assistance patients. The company’s products comprise artificial respiratory, endotrachael tubes, biomedical acoustics, SonarMed Airwave, medical devices, disposable …
  • First Horizon National Corporation:企業の戦略・SWOT・財務情報
    First Horizon National Corporation - Strategy, SWOT and Corporate Finance Report Summary First Horizon National Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • A. K. Capital Services Ltd (530499):企業の財務・戦略的SWOT分析
    A. K. Capital Services Ltd (530499) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆